Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

(2013) B. Cariou et al.   DIABETES CARE

Activation of intestinal peroxisome proliferator-activated receptor-  increases high-density lipoprotein production

(2012) S. Colin et al.   EUROPEAN HEART JOURNAL

Protection from liver fibrosis by a peroxisome proliferator-activated receptor   agonist

(2012) K. Iwaisako et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PPARs: Fatty acid sensors controlling metabolism

(2012) Lars la Cour Poulsen et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2012) Yoshihisa Takahashi   WORLD JOURNAL OF GASTROENTEROLOGY

Peroxisome Proliferator–Activated Receptor-α Gene Level Differently Affects Lipid Metabolism and Inflammation in Apolipoprotein E2 Knock-In Mice

(2011) Fanny Lalloyer et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Roles of PPARs in NAFLD: Potential therapeutic targets

(2011) Anne Tailleux et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Effects of the New Dual PPAR /  Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism

(2011) B. Cariou et al.   DIABETES CARE

The PPARβ/δ Activator GW501516 Prevents the Down-Regulation of AMPK Caused by a High-Fat Diet in Liver and Amplifies the PGC-1α-Lipin 1-PPARα Pathway Leading to Increased Fatty Acid Oxidation

(2011) Emma Barroso et al.   ENDOCRINOLOGY

MBX-8025, A Novel Peroxisome Proliferator Receptor-δ Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin

(2011) Harold E. Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Peroxisome proliferator-activated receptor-α agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis

(2011) Claire Z Larter et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

PPARα Expression Protects Male Mice from High Fat–Induced Nonalcoholic Fatty Liver

(2011) Mohamed A. Abdelmegeed et al.   JOURNAL OF NUTRITION

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis

(2011) Lisa B. Van Wagner et al.   Therapeutic Advances in Gastroenterology

Recent advances in nonalcoholic fatty liver disease

(2010) Onpan Cheung et al.   CURRENT OPINION IN GASTROENTEROLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review: Treatment options for nonalcoholic fatty liver disease

(2010) Brian Lam et al.   Therapeutic Advances in Gastroenterology

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

(2009) Vlad Ratziu et al.   HEPATOLOGY

Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance

(2008) Justin I. Odegaard et al.   Cell Metabolism

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

(2008) C. Fernández-Miranda et al.   DIGESTIVE AND LIVER DISEASE

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY